Cell-Easy Expands Toulouse R&D Facility to Advance Three Next-Generation Cell Therapy Manufacturing Programs
Toulouse, September 3, 2026
Cell-Easy, a specialized Contract Development and Manufacturing Organization (CDMO) dedicated to cell therapy, today announced the expansion of its R&D capabilities with the addition of >50 m² of new laboratory space at its Toulouse facility.
The expansion strengthens Cell-Easy’s ability to conduct multiple development and scale-up programs in parallel, supporting customers and internal innovation projects from process development through technology transfer and GMP manufacturing readiness. The new laboratory will accommodate up to six members of Cell-Easy’s Development Department, further increasing the company’s capacity to execute internal and customer programs.
The expanded facilities will support three strategic programs focused on the future of cell therapy manufacturing:
• Scaling up allogeneic NK cell manufacturing
Cell-Easy is developing a larger-scale manufacturing process for an allogeneic NK cell therapy, increasing batch size to treat more patients per run while targeting a ten-fold reduction in manufacturing cost per dose.
• Streamlining G-Rex®-based CAR-T manufacturing
Building on work supported by the ScaleReady G-Rex® Grant, Cell-Easy is optimizing its G-Rex®-based CAR-T process — reducing consumable use, process duration and hands-on time to lower manufacturing costs and simplify GMP operations.
• Advancing BetaCure: scalable manufacturing for iPSC-derived beta cells
Through its internal BetaCure program, Cell-Easy is building a robust, economically viable manufacturing process for iPSC- derived pancreatic beta cells — addressing one of the field’s key bottlenecks on the path to clinical-scale production.
“This expansion, coming only one year after the extension of our GMP manufacturing facilities, is an important milestone in Cell-Easy’s development as a credible and specialized cell therapy CDMO” said Guillaume Lay, Chief Commercial Officer at Cell-Easy. “Our ambition is to provide our customers with a fully integrated development and manufacturing partner, combining deep cell therapy expertise with the flexibility and responsiveness required by innovative biotech companies. By investing simultaneously in our development and GMP capabilities, we are strengthening our ability to take programs from process development through to clinical manufacturing.”
With expertise spanning process and analytical development, technology transfer, GMP manufacturing and CMC support, Cell-Easy continues to expand its capabilities as a dedicated partner for the development and manufacturing of cell therapy products
About Cell-Easy
Cell-Easy is a science-driven CDMO specialized in advanced Cell Therapies. Cell-Easy offers a broad range of Services, including Process & Analytical development, GMP manufacturing and CMC/Regulatory support for global Biotechs & Pharmas. The scientific team and QbD approach enable seamless technology transfer and development for cell-based therapies in the fields of oncology, autoimmune diseases and regenerative medicine (T cells, NK cells, Macrophages, MSCs, HSCs and any immortalized cell lines). In addition to its role as a conventional CDMO, Cell-Easy provides a range of added-value services, including: i) access to patients through an extensive network of national clinicians, ii) access to the human biological materials required to produce cell therapies, and iii) comprehensive CMC and regulatory support to accelerate the market approval of these cutting-edge therapies.
Explore our services at https://www.cell-easy.com and don’t hesitate to contact us at info@cell-easy.com